| Autor: |
Amador-Licona N; Department of Education and Research, UMAE HE No.1, Bajio, Instituto Mexicano del Seguro Social, Mexico City, Mexico., Díaz-Murillo TA; Department of Education and Research, UMAE HE No.1, Bajio, Instituto Mexicano del Seguro Social, Mexico City, Mexico., Gabriel-Ortiz G; Laboratory of oxidative stress & Pathology, Centro de Investigacion Biomedica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Mexico., Pacheco-Moises FP; Department of Chemistry, University of Guadalajara, Guadalajara, Mexico., Pereyra-Nobara TA; Department of Education and Research, UMAE HE No.1, Bajio, Instituto Mexicano del Seguro Social, Mexico City, Mexico., Guízar-Mendoza JM; University DeLa Salle Bajio, Leon, Mexico., Barbosa-Sabanero G; Department of Research, University of Guanajuato, Leon, Mexico., Orozco-Aviña G; Institute of Research on Inflammation, Guadalajara, Jalisco, Mexico., Moreno-Martínez SC; Department of Education and Research, UMAE HE No.1, Bajio, Instituto Mexicano del Seguro Social, Mexico City, Mexico., Luna-Montalbán R; Department of Education and Research, UMAE HE No.1, Bajio, Instituto Mexicano del Seguro Social, Mexico City, Mexico., Vázquez-Valls E; Laboratory of oxidative stress & Pathology, Centro de Investigacion Biomedica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Mexico. |
| Abstrakt: |
HIV-seropositive patients show high incidence of coronary heart disease and oxidative stress has been described as relevant key in atherosclerosis development. The aim of this study was to assess the effect of omega 3 fatty acids on different markers of oxidative stress in HIV-seropositive patients. We performed a randomized parallel controlled clinical trial in The Instituto Mexicano del Seguro Social, a public health hospital. 70 HIV-seropositive patients aged 20 to 55 on clinical score A1, A2, B1 or B2 receiving highly active antiretroviral therapy (HAART) were studied. They were randomly assigned to receive omega 3 fatty acids 2.4 g (Zonelabs, Marblehead MA) or placebo for 6 months. At baseline and at the end of the study, anthropometric measurements, lipid profile, glucose and stress oxidative levels [nitric oxide catabolites, lipoperoxides (malondialdehyde plus 4-hydroxialkenals), and glutathione] were evaluated. Principal HAART therapy was EFV/TDF/FTC (55%) and AZT/3TC/EFV (15%) without difference between groups. Treatment with omega 3 fatty acids as compared with placebo decreased triglycerides (-0.32 vs. 0.54 mmol/L; p = 0.04), but oxidative stress markers were not different between groups. |
